Dr. David Crean
Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.
Erik Martinez-Hackert, Ph.D.
CSO & Founder
Dr. Martinez-Hackert is currently an Assistant Professor of Biochemistry and Molecular Biology at Michigan State University. He was previously a Senior Scientist at Acceleron Pharma, working in a related therapeutic field. Dr. Martinez-Hackert has made seminal contributions to an understanding of the molecular mechanisms and biological functions of the Transforming Growth Factor-ß (a.k.a TGF-ß) family. Dr. Martinez-Hackert’s work is highly multidisciplinary, blending tools of molecular biology, structural` biology, biochemistry, and animal models to confront fundamental problems in obesity, musculosketal development, and cancer. Dr. Martinez-Hackert holds a BS in chemistry from the University of Colone; Germany. He holds a Ph.D. in biochemistry from the Rutgers University. He has authored 27 publications and has 2 patents.
Mr. Senturia is a serial entrepeneur. He has been CEO or chairman of nine companies including: Oberon Fuels, Atcom, Mohomine, Soflinx, and Lonocloud. Mr. Senturia is currently chairman of Talapo Therapeutics and Consortia, and Founder of Abreos Bioscidences. He is currently also CEO of Blackbird Ventures, a small venture fund that is focused on very early stage companies. He has taught entrepreneurship at San Diego State University (in the MBA program) as well as at the University of California, San Diego (Von Liebig School of entrepreneurism in the Division of Engineering).
Craig Harding, J.D/A.B.
Craig Harding is a member of the Board of Directors of Talapo Therapeutics. He’s currently an investor and member of Life Science Angels and Band of Angels. He has expertise in early stage companies and associated governance; corporate and securities work and complex transactions. Craig was previously Founder and Deal Engineer at Deal Labs, and prior to that was General Counsel and Secretary at Tesla Motors, Inc. (now Tesla Inc.) and worked at Tesla from 2006 to 2011. Craig has also served as General Counsel and Secretary at Kaleida Labs (a joint venture of IBM and Apple) and Actra (a joint venture of GE and Netscape). He has a J.D. from Vanderbilt Law School and an A.B. (math) from Duke University.